Journey Medical Corp (DERM)
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Last price
- $4.47
- As of
Kresmion compiles this page from DERM's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Journey Medical Corp (DERM): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-12.
See the full DERM dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for DERM on one page. Preview it with sample data, then open it live with a free account.
Preview the DERM dossierActive events for DERM
- high13F: large increase
CITADEL ADVISORS LLC added +68% to DERM (2026Q2)
- high13F: large reduction
MILLENNIUM MANAGEMENT LLC cut 71% of DERM (2026Q2)
- mediumEarnings below estimates
Q2-2025: Missed consensus by 49.4% - EPS $-0.16 vs $-0.1071 estimate
- lowEarnings below estimates
Q3-2025: EPS $-0.09 vs $-0.0485 estimate, -0.04 on a near-zero consensus
- mediumEarnings above estimates
Q4-2025: Beat consensus by 21.6% - EPS $-0.046 vs $-0.0587 estimate
FREE, NO ACCOUNT
Every event on DERM, as it fires
New filings, 13F moves and cross asset events on DERM land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
DERM positions held by the managers we follow (2026Q2)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP 48115J109 · 2026Q2 | $1.6M | 0.00% |
| MILLENNIUM MANAGEMENT LLC FundCUSIP 48115J109 · 2026Q2 | $779K | 0.00% |
| CITADEL ADVISORS LLC FundCUSIP 48115J109 · 2026Q2 | $582K | 0.00% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, DERM
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
Going concern statement
DERM's 10-Q filed Aug 12, 2026 states:
However, as a result of recurring and historical losses, substantial doubt exists about the Company's ability to continue as a going concern for a period of at least twelve months from the date of issuance of these financial statements.
Read the 10-Q on SEC EDGAR Every company with a going concern statement
More data on DERM
DERM against its peers
DERM's operating margin of -13.3% ranks in the 44th percentile of 16 Drug Manufacturers - Specialty & Generic sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-03-31.
| Metric | DERM | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 61.2M USD | 115M USD | 43 | 14 |
| Gross margin | 65.8% | 43.6% | 77 | 14 |
| Operating margin | -13.3% | -7.7% | 44 | 16 |
| Net margin | -18.7% | -28.7% | 68 | 16 |
| Return on equity | -35.9% | -32.8% | 50 | 12 |
Peers (17): CRDL, BGM, TSNDF, JUSH, GRUSF, AAWH, AKBA, CPIX, ADCT, CRLBF, GLAS, ZYBT, CWBHF, ELTP, TLPH, CGC, LEEEF. Left out: OGI (period gap), PHBI (period gap), ASRT.D (no annual filing), LFCR (no annual filing), CTOR (no annual filing), INCR (period gap), BORAY (no annual filing), CYPA (no annual filing). Fiscal periods ending between 2025-09-30 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (DERM: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in DERM on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on DERM in the last 180 days.
Upstream: SEC EDGAR filings for DERM
Kresmion, "Journey Medical Corp (DERM) institutional holdings and SEC filings", data as of 2026-08-16, https://kresmion.com/research/DERM. Upstream data: SEC EDGAR filings for DERM.
Link to this data (HTML):
<a href="https://kresmion.com/research/DERM">Journey Medical Corp (DERM) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow DERM on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to DERM for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.